

To: Michelle A. Iwamoto and/or Ivor R. Elrifi.

From: Robert M. Kelly

21 March 2012

RE: Proposed Amendments to 10/594,553 for allowance.

46-47. Unaltered.

48. The liposomal formulation according to claim 46, wherein the oligonucleotides ~~are constituted~~
comprise [[5-100]] deoxyribonucleotides, ribonucleotide or chemically modified derivatives thereof,
which are 5-100 bases in length.

(altered to help clear up what is claimed, otherwise, it might not be limited to the base length of 5-100 in the case of the other oligonucleotides.)

49-53. Unaltered.

54. A method of ~~treating~~ delivering an oligonucleotide to a mammal ~~with a drug~~ comprising
administering to the mammal the ~~drug~~ oligonucleotide in the liposomal formulation of claim 46.

(altered to broaden, and remove issues of possession and enablement.)

55-56. Unaltered.

57. The method of claim 54, wherein the liposomal formulation further includes one or more active
substances.

(altered to clear up and coincide with the alterations in Claim 54 to comport with Claim 46.)

58-60. Unaltered.